Clinical Trial Results - Phio Pharmaceuticals reported pathologic complete response (100% tumor clearance) in 2 patients with cutaneous squamous cell carcinoma (cSCC) from the second cohort of its ongoing Phase 1b clinical study [1] - In the second cohort, 1 patient with cSCC showed a partial response (90% tumor clearance) and 1 patient had stable disease without progression [8] - No dose-limiting toxicities or clinically relevant treatment-emergent adverse events were observed in patients receiving intratumoral PH-762, indicating good tolerability [8] PH-762 and INTASYL Technology - PH-762 is an INTASYL compound designed to silence PD-1, potentially offering a non-surgical treatment for skin cancers [9] - INTASYL siRNA gene silencing technology enhances the ability of immune cells to kill tumor cells and has demonstrated efficacy in adoptive cell therapy [6] - The technology targets and silences genes with high specificity across various cell types and tissues without requiring formulation enhancements [6] Study Design and Progress - The ongoing Phase 1b clinical study (NCT 06014086) evaluates the safety and tolerability of neoadjuvant intratumoral PH-762 in patients with Stages 1, 2, and 4 cSCC, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma [5] - The study has enrolled 6 patients with cSCC and 1 patient with metastatic melanoma to date [8] - The company plans to continue enrollment to assess higher dose concentrations of PH-762 [2] Strategic Vision and Leadership Commentary - The company's vision is to strive for a cancer-free future using INTASYL technology, as stated by CEO Robert Bitterman [2] - Mary Spellman, Phio's acting Chief Medical Officer, expressed encouragement over the profound tumor response and reassuring safety data from the second cohort [2]

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical StudyNovember 19, 2024 7:45 AM EST | Source: Phio Pharmaceuticals Corp.--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its ...

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 5:47 PM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells t ...

● . . Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT October 18, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effe ...

● ● . | --- | --- | |----------------------------------------------|-------| | | | | INSTAYL Compound PH-894 at ASGCT's 2024 | | | Advancing Gene and Cell Therapies for Cancer | | October 16, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. PH-894: Potent and Specific Silencing of BRD4 in NK Cells Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by usin ...

. . Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells October 07, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make im ...

Core Insights - Phio Pharmaceuticals Corp. is presenting data on its proprietary INTASYL® siRNA gene silencing technology at the 20th Annual Oligonucleotide Therapeutics Society Meeting in Montreal from October 6th-9th, 2024 [3][4] - The presentation will highlight how INTASYL enhances the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies, including NK, TIL, and CAR-T [4] - INTASYL technology is noted for its simplified chemical composition, which aims to reduce toxicity while improving tolerability and efficacy in therapeutic development [4][5] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology [5] - INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types, primarily enhancing the ability of immune cells to kill tumor cells [5] - INTASYL is unique as it is the only self-delivering RNAi technology that does not require specialized formulations or drug delivery systems [5]

. . Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT August 29, 2024 8:30 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effectiv ...

Core Insights - Phio Pharmaceuticals reported its financial results for Q2 2024, highlighting progress in its clinical trials and financial position [3][10]. Recent Corporate Updates - The Phase 1b clinical trial for PH-762 received a positive safety recommendation, with no dose-limiting toxicities observed, leading to dose escalation and enrollment of the next cohort [3][4]. - A fifth clinical trial site has been added at the University of Pittsburgh Medical Center, joining four other sites [5]. - A new patent for INTASYL RXI-185, targeting aging skin disorders, was granted in South Korea [6]. - The company entered into agreements to exercise warrants for 545,286 shares at a reduced price, generating approximately $3.1 million in gross proceeds [7][11]. - A reverse stock split was executed, reducing outstanding shares from approximately 4.6 million to 0.5 million [8]. - The company is now in compliance with Nasdaq's minimum bid price requirement [9]. - Robert M. Infarinato was appointed as the new CFO effective August 1, 2024 [9]. - An exploratory collaboration was initiated with a global skincare company for cosmeceutical applications [10]. Financial Results - Cash position decreased to $4.7 million as of June 30, 2024, down from $8.5 million at the end of 2023 [10]. - Research and development expenses were $0.9 million for Q2 2024, a 37% decrease from $1.4 million in Q2 2023 [12]. - General and administrative expenses decreased by 10% to $1.0 million in Q2 2024 compared to $1.2 million in Q2 2023 [13]. - The net loss for Q2 2024 was $1.8 million, down from $2.5 million in Q2 2023, primarily due to reduced expenses [14]. Operational Metrics - Total operating expenses for Q2 2024 were $1.9 million, compared to $2.5 million in Q2 2023 [19]. - The net loss per common share for Q2 2024 was $3.62, compared to $13.27 in Q2 2023 [19]. - The weighted average number of common shares outstanding was 510,188 for Q2 2024 [19]. Balance Sheet Highlights - Total assets as of June 30, 2024, were $5.3 million, down from $9.4 million at the end of 2023 [20][21]. - Cash and cash equivalents decreased to $4.7 million from $8.5 million [20]. - Total liabilities were $1.5 million, with total stockholders' equity at $3.8 million [21].

Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for a ...